جست‌وجوی استاد و پژوهشگر

Edward Guntherمشاهده پروفایل

استاد

• Breast Cancer Research
• Oncology
• Molecular Biology
• +۳ مورد دیگر

Edward Gunther, MD is a Professor in the Department of Medicine, Division of Hematology and Oncology at Penn State College of Medicine and the Penn State Cancer Institute. His research focuses on breast cancer mechanisms using genetically modified mouse models to uncover molecular and cell biological mechanisms of cancer development and progression. His research interests include: Breast cancer progression and relapse mechanisms Transgenic mouse modeling of mammary tumors Oncogene function in carcinogenesis Tumor cell heterogeneity and subclone cooperation Minimal residual disease and dormancy Dr. Gunther's recent publications reveal how different oncogenes shape premalignant clone progression in breast cancer models, mechanisms of relapse-proficient subclones with collateral sensitivity to oncogene overdose, and carcinogen-specific mutation patterns in Ras-Raf pathway oncogenes. His work demonstrates how reproductive history influences cancer development and how long-lived premalignant clones can evade natural protective mechanisms. His scientific recognition includes: Outstanding Research Publication award (2014) for his Nature paper on tumor heterogeneity Substantial social media and academic engagement for his research (658 Mendeley readers for the Nature paper) Dr. Gunther has received continuous National Cancer Institute funding as Principal or Co-Principal Investigator for multiple projects spanning nearly two decades: Genetic Analysis of Breast Cancer Progression in Mice Using Inducible Transposition (2017-2018) Modeling breast cancer relapse prevention in mice (2010-2016) Preclinical Modeling of Latent Breast Cancer in Mice (2005-2010) BRCA1 FUNCTION USING AN INDUCIBLE TRANSGENE (1999-2005) His laboratory at the Penn State Cancer Institute's Next-Generation Therapies division maintains an active research program investigating the molecular mechanisms of breast cancer progression, dormancy, and relapse using sophisticated genetically engineered mouse models that closely mimic human disease processes.

Rachel Baileyمشاهده پروفایل

پژوهشگر

• Gene Therapy
• Neurodegenerative Diseases
• Tauopathies
• +۷ مورد دیگر

Rachel Bailey is a researcher at UT Southwestern with a focus on developing gene therapies for neurological disorders. She holds dual bachelor's degrees in Biology/Bioinformatics and Molecular Biology from Rensselaer Polytechnic Institute, a Ph.D. in Neuroscience from the University of Florida, and completed postdoctoral research at the University of North Carolina Chapel Hill. Education : Dual B.S. from Rensselaer Polytechnic Institute, Ph.D. in Neuroscience Her research spans gene therapy for monogenic and complex neurodegenerative diseases, including SLC13A5 epileptic encephalopathy , Giant Axonal Neuropathy , and tauopathies like Alzheimer’s disease. She employs AAV vector engineering for gene replacement and silencing, with expertise in preclinical development and IND-enabling studies . Recent publications highlight her work on tau protein phosphorylation in Parkinson’s disease, AAV9 gene therapy for GAN, and autonomic dysfunction in neurodegenerative models. Key collaboration networks include institutions like the NIH and Mayo Clinic.

• Neurosciences
• Physiology
• Microbiology
• +۵ مورد دیگر

Professor Elisa Hill is a distinguished academic at RMIT University where she serves as a Professor in the Department of Health and Biomedical Sciences within the College of Science. She leads the Gut-Brain Axis Laboratory and holds the significant position of Deputy Chair of the Academic Board at RMIT University. Her career spans prestigious institutions including The University of Melbourne and research collaborations in Paris, France. Professor Hill earned her PhD in Neuroscience from The University of Melbourne in 2002. She subsequently undertook a CNRS postdoctoral position in Paris studying cortical neuronal diversity. Returning to Melbourne in 2006 as an NHMRC Howard Florey Centenary Fellow, she joined Prof Steve Petrou's laboratory to investigate neuronal networks in genetic mouse models of epilepsy. In 2009, she imported the Neuroligin-3R451C mouse model of autism to Australia, establishing herself as a pioneer in gut-brain axis research. Her research program focuses on three interconnected areas: identifying causes of gut dysfunction in transgenic mouse models of neurological disease, determining how neurons communicate with the lymphoid system and inflammation, and understanding interactions between the nervous system and bacteria. Professor Hill has demonstrated that gene variations associated with autism alter neuron populations in the mouse enteric nervous system, affecting gut motility, permeability, microbiome composition, and behavior. Her laboratory has developed sophisticated capabilities including video-imaging assays for gut motility, immunofluorescence for neuronal and immune cell analysis, and whole-cell patch clamp electrophysiology for neuronal activity profiling. Analysis of her recent publications reveals a strong focus on the gut-brain axis in autism, with particular attention to the Neuroligin-3R451C mouse model. Her work spans neuroimmunology, gastrointestinal physiology, microbiome interactions, and behavioral neuroscience, demonstrating an increasingly interdisciplinary approach that integrates molecular, cellular, and systems-level perspectives. A notable trend is the expansion of her research into translational applications, including biomaterial development for urogynaecological health. NHMMRC Howard Florey Centenary Fellowship ARC Future Fellowship RMIT Senior Vice Chancellor's Research Fellowship Professor Hill actively supervises numerous PhD students including Vic Lin, Yuansong Li, and Mohammed Al Alamoudi, among others. Her research has been supported by major funding bodies including NHMRC, US Department of Defense CDMRP, CNRS, ARC, and RMIT. She leads the Gut-Brain Axis Laboratory, which collaborates extensively with researchers across institutions, particularly with Prof Ashley Franks at La Trobe University. The laboratory employs a multidisciplinary team with expertise in neuroscience, microbiology, immunology, and gastrointestinal physiology, utilizing advanced techniques to investigate the complex interactions between the nervous system, immune system, and gut microbiome.

• Virology
• Vaccine Development
• Hepatitis Viruses
• +۵ مورد دیگر

Lars Frelin is an Associate Professor in Virology at Karolinska Institutet, where he also serves as Programme Director for the Study Programme in Biomedical Laboratory Science and the Master Programme in Diagnostic Cytology. He is the Facility Manager for ANA Futura and a member of the VIVAC (Vaccines and Immunotherapies against Viruses And Cancer) research group led by Matti Sällberg at the Department of Laboratory Medicine, Division of Clinical Microbiology. Dr. Frelin's academic background includes: PhD from Karolinska Institutet (2004) Docent (Associate Professor) in Virology, Karolinska Institutet (2013) His research focuses on vaccine development against infectious diseases, particularly hepatitis viruses. Working with the VIVAC research group, he investigates novel immunotherapeutic approaches to combat viral hepatitis B, C, and D. His work spans from basic virology to translational research, with an emphasis on understanding viral immune evasion strategies and developing therapeutic vaccines that can overcome immune tolerance in chronic infections. Dr. Frelin's scientific contributions span over two decades, with recent work focusing on universal coronavirus vaccines, novel prime-boost strategies for hepatitis viruses, and understanding the immune response to viral infections. His research demonstrates a consistent trajectory toward developing immunotherapies that target viral entry mechanisms and enhance host immune responses against persistent viral infections. Dr. Frelin has secured multiple research grants from the Swedish Research Council, including: "Pathogenesis and immune evasion strategies of hepatitis viruses: New transgenic mouse models and new therapies" (2020-2022) "Pathogenesis and immune evasion strategies of hepatitis viruses: New transgenic mouse models and new therapies" (2017-2019) "Understanding the hepatitis C virus nonstructural 5A protein: A new target for antiviral therapies" (2012-2014) As Programme Director, he oversees academic programs in Biomedical Laboratory Science and Diagnostic Cytology, shaping the education of future laboratory medicine professionals. His leadership extends to serving on the Infrastructure Committee at Karolinska Institutet (2016-2019, 2019-2022) and managing the ANA Futura facility since 2020. Dr. Frelin is an active member of the VIVAC research group, which focuses on developing vaccines and immunotherapies against viruses and cancer. The group employs various approaches including DNA vaccine technology, viral vector systems, and novel delivery methods to enhance immune responses against challenging viral targets.

Vivian Liمشاهده پروفایل

استاد پژوهشی

• Stem Cells
• Tumour Biology
• Developmental Biology
• +۶ مورد دیگر

Vivian Li is a Senior Group Leader and Assistant Research Director at The Francis Crick Institute in London, UK, leading a research group focused on intestinal stem cell biology and colorectal cancer mechanisms. Dr. Li earned her PhD from the University of Hong Kong's Department of Pathology in 2008, researching molecular mechanisms of human colonic development and tumorigenesis, for which she received the Gold Medal Prize. She then completed postdoctoral training with Hans Clevers at the Hubrecht Institute in the Netherlands, funded by the Croucher Foundation Fellowship, focusing on Wnt pathway proteomics and intestinal stem cell genes using transgenic mouse models. Her research program investigates how stem cells maintain healthy gut tissue and what goes wrong during cancer development, with particular emphasis on Wnt signaling pathways. Dr. Li's laboratory utilizes advanced organoid technology ('mini-guts') to study stem cell behavior in three-dimensional cultures, gene editing techniques, and state-of-the-art imaging approaches. Her work spans developmental biology, stem cell research, and cancer biology with significant translational implications. Analysis of her recent publications (2022-2025) reveals a strong focus on cancer stemness mechanisms, intestinal regeneration pathways, Wnt signaling components, and innovative organoid modeling approaches for colorectal cancer. Her research consistently bridges basic science with potential clinical applications in gastrointestinal medicine. Gold Medal Prize for PhD thesis Croucher Foundation Fellowship Dr. Li established her independent laboratory at the MRC National Institute for Medical Research in February 2013 and transitioned to the Francis Crick Institute in 2015. Her research aims to develop tumor-specific therapies for bowel cancer and grow replacement human gut tissue for transplantation or drug testing platforms. She leads a multidisciplinary team utilizing cutting-edge techniques including reverse mouse genetics, ex vivo organoid cultures, and advanced genomic and proteomic analyses to investigate stem cell regulation in health and disease. Her laboratory at the Crick Institute operates within the Biological Research Facility and collaborates extensively with other research groups both within the institute and internationally, contributing significantly to understanding intestinal stem cell niche dynamics and cancer development mechanisms.

Jennifer Bartonمشاهده پروفایل

استاد

• Biomedical Engineering
• Bioinstrumentation
• Biomedical Optics
• +۵ مورد دیگر

Jennifer Barton is a Professor at the University of Arizona in the College of Engineering, with appointments in Biomedical Engineering, Electrical and Computer Engineering, Optical Sciences, and Biosystems Engineering. She serves as the Interim Director of the BIO5 Institute and has held leadership roles such as Department Head of Biomedical Engineering and Interim Vice President for Research. BS and MS in Electrical Engineering from the University of Texas at Austin and University of California Irvine PhD in Biomedical Engineering from the University of Texas at Austin (1998) Her research in Biomedical Optics focuses on developing miniature endoscopes combining optical coherence tomography and fluorescence spectroscopy for early ovarian and colon cancer detection . She also explores light-tissue interaction and dynamic optical properties of blood , leading to novel laser therapies for skin disorders. Her publications span optical imaging device design , cancer detection , and multimodal endoscopes . Recent works emphasize machine learning integration for diagnostic accuracy and 3D printed optical components . Women of Impact Research Innovation & Impact, University of Arizona (2022) Thomas R. Brown Distinguished Chair, College of Engineering (2020) Best Campus Collaborator, Tech Launch Arizona (2019) President's Award, SPIE (2016) She mentors students in biomedical engineering and leads the Tissue Optics Lab , an interdisciplinary team building novel imaging devices for healthcare innovation.

• T cell immunology
• Immune tolerance
• Checkpoint inhibitor immunotherapy
• +۵ مورد دیگر

Martina Damo serves as Assistant Professor in the Department of Medicine, Section of Rheumatology at the University of Chicago School of Medicine, where she joined the faculty in October 2023. She leads a research laboratory investigating immune checkpoint receptors on T cells and their role in immunological tolerance, with particular focus on how checkpoint blockade immunotherapy causes immune-related adverse events (irAEs) in cancer patients. Her work aims to identify druggable tolerance pathways and develop bioengineered therapies for tolerance modulation. Dr. Damo's educational background includes: PhD in Bioengineering from Swiss Federal Institute of Technology in Lausanne (EPFL), 2016 Postdoctoral Fellowship in Immunobiology at Yale University, 2022 Instructor position at Yale University, 2023 Her research centers on T cell immunology in physiological and pathological contexts, with emphasis on peripheral tissue immunity. She investigates mechanisms of immune tolerance in skin and liver environments, neoantigen recognition by T cells, and the pathogenesis of irAEs following cancer immunotherapy. Her laboratory employs advanced techniques including clonal lineage tracing, mouse models of cancer and autoimmunity, and bioengineering approaches for therapeutic development. Analysis of her publication history (2011-2025) reveals an evolving research trajectory from foundational work in antigen-specific tolerance and gene therapy (2011-2015) to contemporary focus on T cell exhaustion, checkpoint biology, and cancer immunotherapy applications (2018-2025). Her most cited works involve CD8+ T cell dynamics in tumors and viral infections, with consistent emphasis on translational applications. Key thematic areas include T cell tolerance mechanisms, irAE pathogenesis, and bioengineered tolerance-inducing therapeutics. Dr. Damo actively mentors within her research laboratory and collaborates extensively with immunology researchers including Jeffrey Hubbell, Thomas Gajewski, and Melody Swartz. Her work has attracted significant attention with multiple publications exceeding 100 citations, substantial social media engagement (over 250 X posts), and patent references (23 patents citing her work). She maintains active research funding supporting her laboratory's investigations into T cell tolerance pathways. Her laboratory operates within the University of Chicago's immunology research ecosystem, collaborating with colleagues in the Department of Medicine including Maria-Luisa Alegre and James Curran. Current projects focus on developing targeted approaches to prevent irAEs while preserving anti-tumor efficacy of checkpoint inhibitors, leveraging her expertise in tissue-specific immune regulation.

• Neurodegenerative Diseases
• Alzheimer's Disease
• Tau Protein Biology
• +۳ مورد دیگر

Dr. Charles Harrington is a Senior Research Fellow at the University of Aberdeen's School of Medicine, Medical Sciences and Nutrition. With a background in microbiology, he has transitioned to become a leading researcher in neurodegenerative diseases, particularly focusing on Alzheimer's disease and tau protein biology. His career spans over four decades, with significant contributions to understanding the molecular mechanisms of protein aggregation in neurodegenerative conditions. BSc (Hons) Microbiology, University of Glasgow (1977) PhD Microbiology, University of Glasgow (1980) Harrington's research interests center on the biology of tau protein in aging and Alzheimer's disease, with emphasis on diseases characterized by protein aggregation and methods to prevent these processes. His work has evolved from early studies on microbial cell walls to current investigations of tau pathology, demonstrating remarkable interdisciplinary expertise. He has developed assays for screening tau aggregation inhibitors and has extensively studied the therapeutic potential of hydromethylthionine. Analysis of his recent publications (2021-2025) reveals a strong focus on tau protein aggregation mechanisms, neuroinflammation, synaptic dysfunction in neurodegenerative diseases, and the therapeutic effects of tau aggregation inhibitors. His work frequently examines interactions between different therapeutic approaches, particularly how cholinesterase inhibitors might interfere with tau-targeting treatments. Harrington's research bridges molecular mechanisms with clinical applications, contributing significantly to the development of biomarkers and therapeutic strategies for Alzheimer's disease and related tauopathies. As Chief Scientific Officer for TauRx Therapeutics Ltd, Harrington oversees non-clinical activities for a company conducting phase 3 trials of hydromethylthionine. His collaborative work spans multiple international institutions, with numerous co-authors across neuroscience, biochemistry, and clinical research fields. While specific grant information isn't detailed in the provided text, his extensive publication record suggests substantial research funding support over his career. Harrington's laboratory work appears focused on tau transgenic mouse models, particularly investigating how tau pathology affects synaptic function, neurotransmitter systems, and behavioral outcomes. His research team has developed sophisticated methods for studying protein aggregation and its consequences in neurodegenerative disease models.

Reilly T. Enosمشاهده پروفایل

استادیار

• Obesity
• Metabolic Disease
• Sex Differences in Metabolism
• +۹ مورد دیگر

Reilly T. Enos, PhD, is an Assistant Professor in the Department of Pathology, Microbiology & Immunology at the University of South Carolina School of Medicine. His research focuses on the molecular mechanisms of sex differences in obesity, particularly metabolic and inflammatory processes influenced by sex steroids. The Enos Lab employs rodent models and advanced metabolic phenotyping to investigate menopause-related metabolic dysfunction and complementary therapies. PhD, Exercise Science (Applied Physiology), University of South Carolina, 2013 Post-Doctoral, Complementary and Alternative Medicine in Cancer and Obesity, University of South Carolina School of Medicine, 2017 MS, Exercise Physiology, Baylor University, 2009 BS, Dietetics, University of Northern Colorado, 2010 BA, Spanish & Physical Education, College of Wooster, 2007 Dr. Enos’s research spans immunometabolism, obesity, cancer cachexia, and gut microbiota. His work explores how dietary components (e.g., quercetin, emodin), hormonal status (especially estrogen), and immune modulation (e.g., miR-155, macrophages) influence metabolic and oncological outcomes. He investigates sex-specific responses to high-fat diets, inflammation, and therapeutic interventions using transgenic and diet-induced mouse models. His recent publications highlight trends in metabolic physiology, inflammation, and cancer, often examining the interplay between adipose tissue, immune cells, and hormonal regulation. Key themes include the impact of vivarium conditions on reproducibility, the role of microRNAs in tumorigenesis, and the safety and efficacy of natural compounds. Dr. Enos has not been awarded any listed scientific prizes or fellowships in the provided texts. He advises a research team focused on metabolic and inflammatory disease models, frequently collaborating with researchers such as Erin A. Murphy and Kandy T. Velázquez. His lab receives funding for studies on obesity, cancer, and complementary medicine, though specific grants are not detailed. The lab is equipped for metabolic phenotyping and rodent model studies. The Enos Lab is dedicated to understanding sex-specific metabolic regulation and developing targeted therapies for obesity and cancer-related metabolic disorders, with a focus on translational relevance and experimental rigor.

Jochen Hermsمشاهده پروفایل

استاد

• Biomedical Neuroscience
• Cellular & Systems Neuroscience
• Behavioral & Cognitive Neuroscience
• +۵ مورد دیگر

Prof. Dr. Jochen Herms serves as Director at the LMU Center for Neuropathology and Prion Research , while maintaining a dual affiliation with the German Center for Neurodegenerative Diseases (DZNE) Munich as Head of Translational Brain Research. His work bridges clinical and experimental neuropathology, focusing on synaptic degeneration in neurodegenerative conditions. Ludwig-Maximilians-Universität München (LMU): Director, Experimental Neuropathology DZNE Munich: Translational Brain Research Research Themes: Primary: Biomedical Neuroscience Secondary: Cellular & Systems Neuroscience Tertiary: Behavioral & Cognitive Neuroscience Key investigations include: Physiological roles of neurodegenerative disease proteins (APP, presenilins, BACE, tau, α-synuclein) In vivo two-photon imaging of transgenic Alzheimer's models Neuronal calcium homeostasis in neurodegeneration High-throughput drug screening for AD/PD Active research collaborations leverage funding from: German Research Foundation (DFG) - Munich Cluster for Systems Neurology (EXC 2145 SyNergy) BMBF, BMWi, EU consortia Bavarian Research Foundation Wilhelm Sander Foundation

• Neurodegenerative Diseases
• Alzheimer's Disease
• Parkinson's Disease
• +۱۲ مورد دیگر

Frédéric Calon is a Full Professor in the Faculty of Pharmacy at Université Laval, where he leads a prominent research program focused on neurodegenerative disorders, particularly Alzheimer’s and Parkinson’s diseases. His work bridges molecular neuroscience, nutritional interventions, and blood-brain barrier drug delivery, using both animal models and human post-mortem studies. He is actively involved in training graduate students and postdoctoral fellows and maintains international collaborations, including the LIA OptiNutriBrain with Bordeaux. B.Sc. in Biochemistry, Université Laval (1989–1992) M.Sc. in Pharmacy, Université Laval (1992–1995) B.Pharm., Université Laval (1994–1998) Ph.D. in Pharmacy, Université Laval (1998–2001) Postdoctoral Training, University of California, Los Angeles (UCLA), Dept. of Medicine (2001–2003) Dr. Calon’s research centers on three main axes: (1) the role of nutrition—especially omega-3 fatty acids—in neurodegeneration; (2) synaptic and molecular pathology in Alzheimer’s and Parkinson’s diseases; and (3) the interplay between peripheral metabolic disorders and brain health, including insulin signaling and thermoregulation. He also investigates the blood-brain barrier as a therapeutic gateway for drug delivery. His recent publications reflect a strong focus on Alzheimer’s disease mechanisms, including tau phosphorylation, amyloid-beta pathology, synaptic dysfunction, and the impact of diet and metabolism. He has also made key contributions to understanding essential tremor through post-mortem brain studies. His work frequently involves transgenic mouse models, such as the 3xTg-AD, and integrates behavioral, biochemical, and imaging techniques. Dr. Calon’s research is supported by major grants from CIHR and the Alzheimer Society of Canada. He mentors a large team of doctoral, master’s, and postdoctoral researchers, many of whom are supported by competitive scholarships. His lab has developed unique expertise in in situ brain perfusion and quantitative BBB transport analysis. He leads studies on novel therapeutic strategies, including repurposing beta-3 adrenergic agonists, optimizing nutraceutical formulations, and enhancing brain delivery of biologics via transferrin receptor-targeted vectors. His work on essential tremor has identified GABA receptor deficits and amyloid-beta accumulation in the cerebellum, suggesting a neurodegenerative basis for the disorder.

Bumsoo Ahnمشاهده پروفایل

استادیار

• Mitochondria
• Aging
• Muscle
• +۱۲ مورد دیگر

Bumsoo Ahn, PhD, is an Assistant Professor in the Department of Gerontology and Geriatric Medicine at Wake Forest University School of Medicine. He is also affiliated with the Wake Forest Institute for Regenerative Medicine, Center for Redox Biology and Medicine, Sticht Center for Healthy Aging and Alzheimer’s Prevention, Cardiovascular Sciences Center, Comprehensive Cancer Center, Center for Precision Medicine, and the Center for Vaccines at the Extremes of Aging. His educational background includes a BS from Yonsei University (2004), an MS from the University of North Carolina at Chapel Hill (2011), and a PhD from the University of Florida (2015). Dr. Ahn's research focuses on the mechanisms of muscle aging and wasting, particularly sarcopenia and cancer cachexia. His work emphasizes mitochondrial redox biology, oxidative stress, and the role of reactive oxygen species in muscle dysfunction. He employs transgenic mouse models to investigate causal relationships and test potential interventions, including unacylated ghrelin. His research spans molecular, cellular, and physiological levels, aiming to extend active and functional lifespans. His recent publications highlight investigations into mitochondrial hydrogen peroxide scavenging, SERCA activity restoration, neuronal SOD1 expression, and pharmacological protection against diaphragm dysfunction. These studies reflect a strong interdisciplinary focus on redox biology, muscle physiology, aging, and translational therapeutics. Scientific Awards: No awards listed in the provided text. Dr. Ahn contributes to graduate education through the Molecular Medicine and Translational Science PhD program and the Integrative Physiology and Pharmacology PhD program. His laboratory operates at the intersection of aging, regenerative medicine, and redox biology, engaging in collaborative research with multiple centers. While specific grants are not mentioned, his affiliations suggest involvement in federally and institutionally funded research initiatives focused on healthy aging and disease mitigation. The Ahn Lab investigates mitochondrial redox biology and muscle contractile properties in the context of aging and chronic diseases, utilizing animal models to identify therapeutic strategies for preserving muscle function.

Kathleen Mulvaneyمشاهده پروفایل

استادیار

• Cancer Biology
• Protein-Protein Interactions
• Cancer Therapeutics
• +۷ مورد دیگر

Kathleen Mulvaney is an Assistant Professor at the Fralin Biomedical Research Institute at Virginia Tech and in the Department of Biomedical Sciences and Pathobiology at the Virginia-Maryland College of Veterinary Medicine. Her laboratory is located at the Children's National Research & Innovation Campus in Washington, D.C., where she leads research efforts focused on cancer biology and therapeutic development. Dr. Mulvaney's educational background includes: Ph.D. in Cell Biology from the University of North Carolina, Chapel Hill B.S. in Biology from the University of Rochester Dr. Mulvaney's research program centers on understanding and disrupting protein-protein interactions and protein modifications in cancer, with particular focus on pancreatic cancer and pediatric and adult brain cancers. Her laboratory investigates tumor dependencies - the specific enzymes and pathways that cancers rely on for survival - with the goal of translating these findings into meaningful clinical improvements for patient care. A significant portion of her recent work has focused on PRMT5, an enzyme found in approximately 15% of human cancers, exploring how to target this enzyme for therapeutic benefit. Her research employs CRISPR gene editing, molecular biology techniques, and biochemical approaches to identify vulnerabilities in cancer cells. Her laboratory has made significant contributions to understanding the molecular basis of substrate recruitment to the PRMT5 methylosome and has discovered first-in-class inhibitors of the PRMT5-substrate adaptor interaction. Recent work published in Cancer Research demonstrates a promising combination therapy approach for hard-to-treat cancers that lack specific tumor suppressor genes. These cancers, which include certain lung, brain, and pancreatic tumors, become dependent on PRMT5 for survival, making it a potential therapeutic target. Dr. Mulvaney has received numerous scientific awards and honors, including: National Institutes of Health F32 Ruth L. Kirschstein Postdoctoral Individual National Research Service Award (2018-2021) National Institutes of Health LRP Award (2019-2021) Sigma Xi Research Society Graduate Student Travel Award (2015) National Science Foundation Graduate Research Fellowship Honorable Mention (2011, 2012) Dr. Mulvaney actively mentors graduate students and postdoctoral researchers in her laboratory at the Children's National Research & Innovation Campus. Her research is supported by grants from the National Institutes of Health, including an R35 grant to examine cancer-related enzymes. She collaborates extensively with researchers across Virginia Tech and Children's National Hospital to advance cancer research and therapeutic development, participating in the Virginia Tech Cancer Research Alliance which brings together scientists and physicians to develop innovative approaches to cancer treatment. The Mulvaney Lab is part of the Cancer Research Center - D.C. at the Children's National Research & Innovation Campus, where they work alongside other researchers in the Children's Cancer and Immunobiology Center. This collaborative environment allows for interdisciplinary approaches to understanding cancer biology and developing novel therapeutic strategies, with particular emphasis on translating basic science discoveries into clinical applications for hard-to-treat cancers.

David M. Smithمشاهده پروفایل

استاد

• Proteasome Function
• Cancer Biology
• Neurodegenerative Diseases
• +۳ مورد دیگر

David M. Smith is a Professor at the West Virginia University School of Medicine , holding dual appointments in the Biochemistry and Molecular Medicine and Neuroscience departments. He is also a member of the WVU Cancer Institute and affiliated with the Rockefeller Neuroscience Institute . PhD from the University of South Florida School of Medicine Postdoctoral training at Harvard Medical School Research Focus : Molecular mechanisms of proteasome function, including substrate recognition, unfolding, and degradation. His work bridges fundamental enzymology with translational applications in cancer therapy and neurodegenerative diseases like Alzheimer's and Parkinson's. Key Article Trends : Recent publications emphasize proteasome activation mechanisms , neurodegenerative disease models , and structural insights into ATPase function . Grants : NIH R01 GM107129 (Mechanisms regulating proteasomal degradation), NIH R01 AG064188 (Proteasome function in Alzheimer's), and collaborations on projects like Protein-unfolding chaperones for blindness treatment . Lab Personnel : Includes graduate students Thomas Bradley, David Salcedo-Tacuma, Giovanni Howells, and Md Qamrul Islam, along with research technicians and undergraduates. Training emphasizes biochemical, biophysical, and computational techniques.

Masmudur Rahmanمشاهده پروفایل

استادیار

• Molecular Virology
• Cancer Biology
• Oncolytic Viruses
• +۳ مورد دیگر

Masmudur Rahman is an Assistant Professor at Arizona State University (ASU), affiliated with the School of Life Sciences and the Biodesign Center for Personalized Diagnostics. He leads research on molecular virology, focusing on oncolytic viruses like myxoma virus (MYXV) to treat cancers, particularly leveraging their ability to target cancer cells with compromised innate immunity. His work combines virology, genetic engineering, microscopy, and bioinformatics. Education highlights include a BSc and MSc from the University of Dhaka, a PhD in Molecular Virology from the Indian Institute of Science (IISc), and postdoctoral research at the University of Western Ontario and University of Florida, studying poxvirus immune modulation. He has received grants from NIH and the Arizona Biomedical Research Commission for projects on cancer virotherapy and virus-host interactions. Research interests span viral host range mechanisms, tumor tropism, and combination therapies (e.g., selinexor + MYXV). His lab develops strategies to enhance viral efficacy using stem cells and explores autosis induction in CAR-T cells. He teaches undergraduate research and honors courses in microbiology and cell biology, emphasizing hands-on training in virology techniques. Grants include NIH-funded studies on overcoming CAR-T resistance via autosis and targeting metastatic cancers with MYXV-selinexor combinations. His work has been published in Viruses , Cancer Research Communications , and International Journal of Molecular Sciences , among others.